Mantle cell lymphoma
Updates to Article Attributes
Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) and accounts for ~5% of all NHL. It is a malignant neoplasm of virgin B cells that closely resemble normal mantle zone B cells surrounding germinal centres.
Epidemiology
They occur in older adults (mean age ~60 years). There is a recognised male predilection (M:F: F of ~4:1) 2.
MCL is usually widespread at diagnosis and frequently involves, apart from lymph nodes, the spleen, bone marrow, and gastrointestinal tract.
Pathology
MCL is characterised by an infiltrate of small to medium-sized cells with folded nuclei and scant cytoplasm. The diagnosis of MCL is confirmed by histological assessment and immunohistochemical evaluation, including cyclin D1.
Genetics
Many cases have the t(11;14)(q13;q32) translocation that causes overexpression of cyclin-D1 2.
Treatment and prognosis
Survival is short with a ~50% 5-year survival. Over one-third of the patients can die within a year despite the administration of aggressive combination chemotherapy.
-<p><strong>Mantle cell lymphoma (MCL)</strong> is a type of <a href="/articles/non-hodgkin-lymphoma">non-Hodgkin lymphoma</a> (NHL) and accounts for ~5% of all NHL. It is a malignant neoplasm of virgin B cells that closely resemble normal mantle zone B cells surrounding germinal centres.</p><h4>Epidemiology</h4><p>They occur in older adults (mean age ~60 years). There is a recognised male predilection (M:F of ~4:1) <sup>2</sup>.</p><p>MCL is usually widespread at diagnosis and frequently involves, apart from lymph nodes, the spleen, bone marrow, and gastrointestinal tract.</p><h4>Pathology</h4><p>MCL is characterised by an infiltrate of small to medium-sized cells with folded nuclei and scant cytoplasm. The diagnosis of MCL is confirmed by histological assessment and immunohistochemical evaluation, including cyclin D1.</p><h5>Genetics</h5><p>Many cases have the t(11;14)(q13;q32) translocation that causes overexpression of cyclin-D1 <sup>2</sup>.</p><h4>Treatment and prognosis</h4><p>Survival is short with a ~50% 5-year survival. Over one-third of the patients can die within a year despite the administration of aggressive combination chemotherapy.</p>- +<p><strong>Mantle cell lymphoma (MCL)</strong> is a type of <a href="/articles/non-hodgkin-lymphoma">non-Hodgkin lymphoma</a> (NHL) and accounts for ~5% of all NHL. It is a malignant neoplasm of virgin B cells that closely resemble normal mantle zone B cells surrounding germinal centres.</p><h4>Epidemiology</h4><p>They occur in older adults (mean age ~60 years). There is a recognised male predilection (M: F of ~4:1) <sup>2</sup>.</p><p>MCL is usually widespread at diagnosis and frequently involves, apart from lymph nodes, the spleen, bone marrow, and gastrointestinal tract.</p><h4>Pathology</h4><p>MCL is characterised by an infiltrate of small to medium-sized cells with folded nuclei and scant cytoplasm. The diagnosis of MCL is confirmed by histological assessment and immunohistochemical evaluation, including cyclin D1.</p><h5>Genetics</h5><p>Many cases have the t(11;14)(q13;q32) translocation that causes overexpression of cyclin-D1 <sup>2</sup>.</p><h4>Treatment and prognosis</h4><p>Survival is short with a ~50% 5-year survival. Over one-third of the patients can die within a year despite the administration of aggressive combination chemotherapy.</p>
Unable to process the form. Check for errors and try again.